Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

January 8, 2024

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

December 26, 2023

Harpoon Therapeutics Strengthens Leadership Team

December 19, 2023

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

December 11, 2023

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

November 9, 2023

Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 2, 2023

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

October 23, 2023

Harpoon Therapeutics Announces Up to $150 Million Private Placement

October 21, 2023

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

October 16, 2023

Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

October 9, 2023

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2024. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations